Scott Novak to Head New Battelle Research Program on Opioid Addiction and Treatment

Battelle expands its tobacco research program to include opioids,
marijuana

COLUMBUS, Ohio–(BUSINESS WIRE)–In a time of increasing acceptance of marijuana use and a growing crisis
of opioid addiction, Battelle
intends to boost its research into the effects of these substances with
scientific insight and observations.

The platform for doing so is based on forty years of experience in
clinical and behavioral research on tobacco and its physical and
psychological effects on users. As new state laws legalizing marijuana
have swept the nation in the past few years, Battelle leveraged that
experience to include studying recreational and medical marijuana. Now,
it looks to support new partnerships with federal, state and local
stakeholders in the fight against opioid abuse.

To that end, Scott Novak, PhD, has joined Battelle as a Senior Research
Scientist and Research Director for Substance Abuse in its Health and
Consumer Solutions unit. His extensive career has focused on
prescription drugs, including prescription opioid abuse and medical
marijuana. At Battelle, he will lead a transdisciplinary and
translational team of data scientists, policy and evaluation experts and
bench scientists to characterize how biological pre-disposing factors,
such as genetic and neurological function, help shape positive
medication utilization across different state and federal policy
environments.

The program will enrich an already robust portfolio of substance use
research and contribute to Battelle’s rapidly growing body of research
into the potential health consequences of marijuana use which is led by
Erica Peters, PhD.

“As we analyze the public health needs we can address as a scientific
organization, it’s become apparent that we should apply our existing
expertise to the growing problem posed by opioid use,” said Joe Berger,
Battelle’s General Manager of Health and Consumer Solutions. “And
marijuana acceptance and availability is on the rise as more states
legalize it for medical or recreational use. Policy makers need clear
research to aid the understanding of the public health implications of
marijuana product. Bringing Scott Novak aboard is a big step toward
realizing those organizational goals.”

Prior to joining Battelle, Novak worked for RTI International, where he
directed the program of research on prescription drug abuse within RTI’s
Behavioral Health Epidemiology Program. He has served as Principal
Investigator on numerous National Institutes of Health (NIH) grants and
commercial projects. He holds a Ph.D. in Quantitative Sociology from the
University of Kentucky at Lexington; an M.A. in Medical Sociology from
the University of Kentucky at Lexington; an M.S. in Statistics (Honors)
from Harvard University; a B.S. in Statistics from the University of
Wisconsin at Madison and a B.A. in Sociology from the University of
Wisconsin at Madison. He has authored more than 100 papers and
presentations and continues to publish extensively.

About Battelle

Every day, the people of Battelle apply science and technology to
solving what matters most. At major technology centers and national
laboratories around the world, Battelle conducts research and
development, designs and manufactures products, and delivers critical
services for government and commercial customers. Headquartered in
Columbus, Ohio since its founding in 1929, Battelle serves the national
security, health and life sciences, and energy and environmental
industries. For more information, visit www.battelle.org.

Contacts

Battelle
Katy Delaney, 614-424-7208
delaneyk@battelle.org
or
T.R.
Massey, 614-424-5544
masseytr@battelle.org